US OTC market size
$52B
↑ 4.8% CAGR to 2028
Category disruption
PE Ruling
↓ Oral phenylephrine ruled ineffective
Fastest growing format
Topical NSAID
↑ Rx-to-OTC converts outpacing oral
Pipeline watch
Rx-to-OTC
Migraine Rx candidates in FDA review
Top five signals this month Ranked by consultant relevance
01
Sun Care Dermatology
Bemotrizinol debuts on US shelves

Ultra Violette's Unblock Screen SPF 50 launched August 31, 2026 as the first US sunscreen to use bemotrizinol, sold through Sephora. dsm-firmenich's Parsol Shield ingredient is also reaching other formulators, and a follow-up Ultra Violette product is planned for January 2027.

So what: The exclusivity window referenced in the prior edition is now running from an actual launch date rather than just an approval date. Clients weighing a bemotrizinol-based launch should treat the clock as already started, not pending.
Velocity
02
Cough, Cold & Allergy Regulatory/Market Access
Phenylephrine's regulatory story splits in two directions at once

FDA's oral phenylephrine removal order, proposed November 2024 with comments closing May 2025 and once expected "sometime in 2026," still has not published. Meanwhile a narrower August 2026 Federal Register amendment recognized phenylephrine bitartrate as safe and effective specifically in effervescent dosage form (alone, or combined with aspirin and chlorpheniramine), removing sinusitis as a permitted indication in that form.

So what: The narrow effervescent opening is a monograph-compliant reformulation path, not a resolution of the oral-PE question. Category planning should still assume oral PE removal eventually proceeds, but brands can keep selling existing oral products today and should not over-commit reformulation budgets to a date FDA has not confirmed.
Velocity
03
Rx-to-OTC candidates Regulatory/Market Access
A third naloxone product switches from prescription to OTC

FDA approved Rextovy, a 4 mg naloxone nasal spray from Amphastar, for OTC sale on June 16, 2026, joining Narcan and RiVive as the third Rx-to-OTC naloxone switch. Competition has already pushed retail prices down, from Narcan's original $44.99 two-pack toward a $19 CalRx generic. Rextovy's OTC price was not yet set as of this edition, and the product was not yet stocked at major chains.

So what: This is the clearest Rx-to-OTC switch precedent outside the three core verticals. Clients in adjacent categories (naloxone, other emergency-use Rx products) should watch this switch pathway and its pricing dynamics as a template.

Consumer search and social signals also inform velocity rating.

Velocity
04
Regulatory/Market Access
OMUFA II keeps the modernized monograph pathway funded through FY2030

FDA's OMUFA reauthorization program page confirms the FY2026-2030 user-fee structure is in effect.

So what: Sponsors can treat an OTC monograph order request as a stable, time-bound alternative to a full Rx-to-OTC switch application for the planning horizon ahead.

Consumer search and social signals also inform velocity rating.

Velocity
05
Digestive Health Claims
GLP-1 claims scrutiny spreads from supplements into OTC-adjacent marketing

FTC enforcement activity, including a settlement with a telemedicine company over GLP-1-related marketing claims, shows the agency applying the same substantiation standard across telehealth and OTC-adjacent brands, not only dietary supplements.

So what: OTC brands relabeling existing SKUs as "GLP-1 companions" face the same claims-exposure risk already flagged in the supplement vertical. Legal review before finalizing claims is the safer path.
Velocity
Ingredients/topics to watch
Bemotrizinol (BEMT)
First new US sunscreen active in 20 years. The first US launch shipped August 31, 2026, so dsm-firmenich's 18-month exclusivity clock now runs from a real launch date.
GLP-1 companion nutrition
Legacy OTC brands are relabeling existing SKUs faster than new clinical evidence is accumulating. Claims exposure, not efficacy, is the near-term risk to watch.
Oral phenylephrine
No final order has published yet. Category planning should assume removal proceeds and reformulation toward pseudoephedrine-behind-counter or non-oral formats is the safer default.
OMUFA II reauthorization
Five-year fee certainty locks in FDA's modernized monograph pathway. Sponsors should treat OTC monograph order requests as a viable, time-bound alternative to Rx-to-OTC switch applications.
Regulatory radar
WatchOral phenylephrine final order still unpublished. Proposed November 2024; comments closed May 2025. FDA has not met its "sometime in 2026" expectation.
MonitorGLP-1 companion claims. The FTC is applying the same substantiation standard to telehealth and OTC-adjacent brands as to supplements.
ClearedBemotrizinol on shelf. First US launch shipped August 31, 2026; the exclusivity window is now running.
ClearedPhenylephrine bitartrate recognized in effervescent dosage form under an August 2026 monograph amendment.
ClearedOMUFA II funding secured through FY2030, confirming FDA's monograph order pathway is operating on a durable schedule.